TCG Lifesciences Limited (TCGLS) announced the nomination of its pre-clinical development candidate under a R&D collaboration entered into in 2009 with Pfizer Inc. As per the agreement, Pfizer will own the candidate and other back up candidates while TCGLS will receive a milestone payment for its success in moving these molecules to the candidate stage.

The candidate is a small molecule new chemical entity that meets all the success criteria set by Pfizer, including potency, pharmacokinetics, animal pharmacology, toxicology and related parameters. TCGLS’ participation encompasses synthetic chemistry, in-vitro pharmacology, DMPK, in-vivo pharmacology, and preliminary safety.

“This achievement reflects TCGLS’ in-depth expertise and ability to work in partnerships. We are delighted to meet our commitment of delivering the candidate in less than two years time,” said Dr Sourav Basu, AVP, TCG Lifesciences. Swapan Bhattacharya, managing director, TCG Lifesciences, remarked that the company has  established an excellent track record in their long term collaboration with Pfizer and this candidate nomination is a key milestone of the success of this partnership. Bhattacharya said, “This success also demonstrates the progress made by TCGLS in supporting innovation. I sincerely acknowledge the dedication of both the Pfizer and TCGLS scientific teams and congratulate them for this achievement.”